Crimson Publishers-Surgical Medicine Open Access Journal

Bortezomib-Induced Blepharitis: A Case Report   by Kamal AlZahran in  Crimson Publishers: Open access journal of surgery impact factor Bortezomib is a proteasome inhibitor approved for the treatment of multiple myeloma and has known manageable toxicities. Blepharitis is an inflammatory condition of the eyelid that leads to formation of chalazia both causing visual field disturbance. Bortezomib induced blepharitis has not been well reported in the literature. we present a case of 76-year-old lady with multiple myeloma who developed bortezomibinduced blepharitis and chalazia. Patient was successfully treated after topical ocular therapy, systemic antibiotherapy and omission of bortezomib.  Multiple myeloma is characterized by a neoplastic proliferation of plasma cells in the bone marrow producing a monoclonal immunoglobulin and resulting in extensive skeletal destruction. One of the used treatment regimens for MM being the VCD protocol (Velcade® or Bortezomib...

Same Story with Different Endings in HER2- Positive Breast Cancer: Why the Benefit of Pertuzumab is Robust in the Metastatic Scenario and Modest in the Adjuvant Setting?  by Shantata J Kudchadkar and Jayesh Sagar* in  Crimson Publishers: Open access journal of surgery impact factor While the incorporation of pertuzumab to a chemotherapy and trastuzumab backbone (dual HER2 blockade) yielded a robust improvement in the outcomes of HER2-positive metastatic patients in the CLEOPATRA study, in the adjuvant setting the same magnitude of benefit was not reproduced with the addition of pertuzumab in the overall population of the APHINITY study, being the reasons for this discrepancy unknown so far. In the present manuscript, we discuss biological and clinical differences between metastatic and early-stage HER2-positive breast cancer that may potentially explain the different magnitudes of benefit observed with pertuzumab in the different disease settings. https://crimso...